Browsing by Author "Silva, Marta Barreto da"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
- Análise de custo-benefício da farmacogenética na terapêutica com varfarinaPublication . Raimundo, Ana; Picanço, Isabel; Silva, Marta Barreto da; Vicente, A.M.
- Biobanco do INSA e a Investigação EpidemiológicaPublication . Silva, Marta Barreto da
- Facts related to the collection of biological samples in the National Health Examination Survey - Portuguese Component of the European Health Examination SurveyPublication . Silva, Marta Barreto da; Francisco, Vânia; Rasteiro, Paula; Sousa, Eduardo; Vicente, A.M.; Bourbon, Mafalda; Martins, Fátima; Seixas, Maria Teresa; Fernandes, Aida; Beleza, Álvaro; Mendonça, Francisco; Gil, Ana Paula; Dias, Carlos MatiasThe objective of the National Health Examination Survey (NHES), which corresponds to the Portuguese component of the European Health Examination Survey (EHES), is to collect health data, related risk factors and biological samples of the Portuguese population, using the EHES recommended methodology. These surveys involve an interview, clinical and physical measurements and blood collection. In this context, we herein describe the pilot study performed in S. Brás de Alportel in the Algarve region. For this pilot study, we have recruited 221 individuals (95 males and 126 females), between 25 and 91 years old, who were enrolled in the Health Centre of S. Brás de Alportel (Algarve). For each participant, we have collected 16.5 ml of total blood, in five different Vacutainer® tubes, which was later processed into serum, plasma and DNA. We have performed several biochemical analyses(total cholesterol, LDL,HDL, glucose, tryglicerides, creatinine, ALT, AST, -GT, CRP and iron) and a complete blood count. From the 221 participants in this pilot study, we were able to collect blood to 219 (99.5%). To 185 of these (84.5%) we were able to collect the total amount of blood. The biochemical analyses were performed in all the samples. The total blood count was performed in 103 samples (47%) due to transport constraints. We have also collected DNA from 210 participants (95.9%). We have created a biobank comprising 1847 serum aliquots and 959 plasma aliquots, which have been stored at - 80°C and 210 DNA aliquots which have been stored at 4°C. In conclusion, during this study, we have optimized the logistics and procedures to perform the large scale study for the NHES and EHES. In addition, we have created a biobank comprising detailed questionnaire data, physical and clinical data and biological samples from a representative sample of S. Brás de Alportel in Algarve, Portugal. This biobank will allow us to perform future studies, including the determination of the prevalence of gene variants of public health interest, the characterization of gene-environment interactions in the development of chronic diseases and the genetic structure of the Portuguese population. The success rate, the quality of the data and of the biological samples was high and comparable to similar studies.
- Genetic variation at the IFITM3 and Influenza A(H1N1)pdm09 infection severity in the Portuguese populationPublication . Gaio, Vânia; Nunes, Baltazar; Pechirra, Pedro; Conde, Patrícia; Guiomar, Raquel; Matias Dias, Carlos; Silva, Marta Barreto daInterferon-inducible transmembrane protein (IFITM3) inhibits the entry of viruses to the host cell, mediating resistance to influenza infection. It has been demonstrated that a genetic variation in the IFITM3 gene (rs12252) alters a splice-site, originating a protein with reduced activity. In this context, our aim was to determine if the C allele of the IFITM3 rs12252 polymorphism is associated with influenza infection or hospitalizations related to Influenza A(H1)pdm09 in the Portuguese population. To achieve our goal, a case-control study design was developed using the nasal swabs collected during the 2009 pandemic, on the context of the National Influenza Surveillance Program. Non-hospitalized influenza cases were defined as patients with influenza like illness (ILI) who tested positive for influenza A(H1)pdm09 and did not require hospitalization. Hospitalized-influenza cases were defined as ILI patients who tested positive for A(H1)pdm09 infection and who were hospitalized. For these cases groups two types of controls were selected: non-hospitalized ILI cases negative for A(H1)pdm09 and hospitalized ILI patients negative for A(H1)pdm09 infection. We have therefore selected 212 non-hospitalized influenza cases, 96 hospitalized influenza cases, 403 non-hospitalized negative controls and 198 hospitalized negative controls. We found that hospitalized negative controls had the highest frequency of allele C carriers (22.5%) and the lowest frequency was found among the non-hospitalized negative controls (11.11%). No association was found between testing positive for A(H1)pdm09 infection (susceptibility to infection) and the C allele of rs12252. We have also found that the risk of being hospitalized (independently of infection status) for the allele C carriers is the highest, after adjustment for age and gender, (OR: 1.59 (95% CI: 1.05-2.43). Our results suggest that the allele C of the IFITM3 rs122252 polymorphism was associated with respiratory disease hospitalizations but not specifically associated with the infection by Influenza A(H1N1)pdm09.
- International Workshop Biobanking for Health Research - AbstractsPublication . Silva, Marta Barreto da; Vicente, A.M.; Neves, Andreia Filipa